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Abstract
Background: For blood purification systems using a semipermeable membrane, the 
convective mass transfer by ultrafiltration plays an important role in toxin removal. The 
increase in the ultrafiltration rate can improve the toxin removal efficiency of the device, 
ultimately reducing treatment time and cost. In this study, we assessed the effects of 
pulsatile flow on the efficiency of the convective toxin removal in blood purification 
systems using theoretical methods.
Methods: We devised a new mathematical lumped model to assess the toxin removal 
efficiency of blood purification systems in patients, integrating the mass transfer model for 
a human body with a dialyser. The human body model consists of a three-compartment 
model of body fluid dynamics and a two-compartment model of body solute kinetics. We 
simulated three types of blood purification therapy with the model, hemofiltration, 
hemodiafiltration, and high-flux dialysis, and compared the simulation results in terms of 
toxin (urea and beta-2 microglobulin) clearance and the treatment dose delivered under 
conditions of pulsatile and non-pulsatile pumping. In vivo experiments were also 
performed to verify the model results.
Results: Simulation results revealed that pulsatile flow improved the convective clearance 
of the dialyser and delivered treatment dose for all three types of therapy. Compared with 
the non-pulsatile pumping method, the increases in the clearance of urea and beta-2 
microglobulin with pulsatile pumping were highest with hemofiltration treatment (122.7% 
and 122.7%, respectively), followed by hemodiafiltration (3.6% and 8.3%, respectively), and 
high-flux dialysis (1.9% and 4.7%, respectively). EKRc and std Kt/V averaged 28% and 23% 
higher, respectively, in the pulsatile group than in the non-pulsatile group with 
hemofiltration treatment.
Conclusions: The pulsatile effect was highly advantageous for all of the toxins in the 
hemofiltration treatment and for β2-microglobulin in the hemodiafiltration and high-flux 
dialysis treatments.
Background
Blood purification systems employing semipermeable membranes are widely used in the
treatment of patients with chronic renal failure (CRF). The mechanisms underlying toxin
removal in these systems are diffusion and convection [1,2]. As shown in Table 1, the con-
vective mass transfer by ultrafiltration (UF) plays an important role in toxin removal [2].
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Thus, the increase in the UF rate can improve the toxin removal efficiency of the device,
eventually requiring less treatment time and cost.
Several experimental studies have indicated that the UF rate in blood purification sys-
tems can be increased by using a pulsatile pump instead of a non-pulsatile pump [3,4].
More specifically, our previous study demonstrated that pulsatile flow can generate a
greater UF rate than non-pulsatile flow due to the increased transmembrane pressure
(TMP) and water permeability of the membrane [3]. However, these studies were limited
to basic in vitro experiments to observe the UF efficiency of the dialyser device itself. To
our knowledge, in vivo evaluations of the device and its application to patients have not
been performed due to difficulties in developing an appropriate animal model. Although
animal experiments regarding urea removal during blood purification treatment are rel-
atively easy to perform, serious difficulties exist in establishing an in vivo animal model
with a high ? 2-microglobulin (B2M) concentration. As noted previously by Cameron [5],
B2M, which is another significant toxin in blood purification, accumulates slowly in the
body under CRF conditions, and therefore, a great deal of time is required for renal fail-
ure associated with a high B2M concentration. However, in vivo analysis is inevitable for
a reasonable assessment of the toxin removal efficiency.
Here, we use a theoretical method as an alternative to in vivo experiment to assess the
effects of pulsatile pump on toxin removal. For this purpose, we devised a new mathe-
matical model to assess the toxin removal efficiency of blood purification systems in
patients, integrating the mass transfer model for a human body [6] with a dialyser in a
blood purification system [2]. The present study focused on whether pulsatile flow can
improve the delivered treatment dose for patients during blood purification. We per-
formed a simple in vivo clinical test to verify the present simulation model by comparing
the simulated urea concentration profile with clinical observations.
Using the mathematical method, we then predicted the dialyser clearances of urea and
B2M for various blood purification therapies using pulsatile and non-pulsatile systems.
In addition, the treatment dose delivered to patients with CRF was predicted under con-
ditions of pulsatile and non-pulsatile blood purification therapy with a long-term dura-
tion of 5 weeks using common blood purification systems, such as hemofiltration (HF),
hemodiafiltration (HDF) and high-flux dialysis (HFx).
Methods
To compare toxin removal efficacy between pulsatile and non-pulsatile systems for the
three types of blood purification therapy (i.e., HF, HDF and HFx), we used a computa-
tional model with in vitro and in vivo experiments. The in vitro experiment to analyze
the contribution of pulsatile flow to the UF rate has already been reported [3] and is
s u m m a r i z e d  i n  A p p e n d i x  A 1 .  W e  i d e n t i f i e d  p a r a m e t e r s  u s e d  i n  t h e  c o m p u t a t i o n a l
Table 1: Blood purification systems using semipermeable membranes
Type of blood purification system Mechanism of toxin removal
Conventional hemodialysis Dialysis
HFx Dialysis + ultrafiltration
HF Ultrafiltration
HDF Dialysis + ultrafiltrationLim and Shim BioMedical Engineering OnLine 2010, 9:31
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model from the results of the in vitro experiment, such as the pressures of the dialyser
inlet and outlet of the blood circuit, and the UF coefficient (Kuf) of the dialyser according
to the blood pumping rate (Qb) and pumping type (pulsatile vs. non-pulsatile). From
these parameters, we theoretically calculated the convective clearance for each type of
therapy. By inserting the calculated convective clearance into the computational model,
we can simulate the hemodynamic and physiological conditions of hemodialysis patients
and assess the effects of pump type and pulsa tility on to xin removal efficacy of the
patients with a long-term duration. To validate the present computational model, the
c o m p u ta t i o n  r e s u l ts  o f  u r ea  r e m o va l  i n  pa t i e n ts  wi t h  CRF  w e r e  c o m pa r ed  wi t h  t h e
results observed in vivo.
Computational model of the diffusion and convection in the dialyser system
The mass transfer inside the body that occurs during blood purification therapy can be
explained roughly using body solutes and fluid exchange kinetics, as described by Ursino
et al. [6]. To simulate the effect of pulsatile flow in a dialyser on the convective clearance
of the three types of blood purification therapy, i.e., HF, HDF, and HFx, we modified the
dialyser model of Depner and Garred [2] for each therapy and combined this with the
human body model of Ursino et al. The human body model is explained briefly below,
and the dialyser model for each therapy is explained in the following two sections.
Body fluid consists of three compartments (intracellular, interstitial and plasma) in the
model, and two compartments (intracellular and extracellular) are used to formulate the
kinetics of the solutes. Fluid exchange between the intracellular and interstitial compart-
ments results from their osmotic pressure difference, whereas oncotic and hydrostatic
pressure gradients induce fluid transfer between the interstitial fluid and plasma. Fluid
exchange between the plasma and dialysate is determined by the UF rate, which is the
product of transmembrane pressure through the dialyser membrane and UF coefficient
of the dialyser. Diffusion is the main mechanism of solute movement into and out of
cells. In the extracellular compartment, the solute kinetics is influenced by mass transfer
through the dialyser in a blood purification system. Here, the model variables related to
solutes include urea and B2M as markers of small and large molecular toxins, respec-
tively, and other important electrolytes (sodium, potassium and chloride) and proteins.
As the meaningful variables were urea and B2M, we discuss only the variations in urea
and B2M, which are markers of uraemic toxins. A schematic diagram of the present
mathematical model is shown in Figure 1. A detailed explanation of the governing equa-
tions and parameters adopted from Ursino et al. [6] is presented in Appendix A2 and
Table 2, respectively.
Convective toxin clearance for HF, HDF and HFx treatments
HF therapy works by passing the patient's blood through a dialyser that filters out waste
products and water and then adds replacement fluid before returning the blood to the
body. The replacement fluid maintains fluid volume in the blood and provides electro-
lytes. The only mechanism of toxin removal in HF therapy is convective transport
through the dialyser membrane. HDF is a method that combines hemofiltration and
counter-current dialysis for diffusive transport. The dialysate flows in the direction
opposite the blood flow in order to maintain the maximum concentration gradient
across the membrane, and the counter-current flow condition increases the efficiency of
dialysis. Consequently, HDF uses both replacement fluid and dialysate solution, and the
mechanism of toxin removal in HDF is both convective and diffusive transport. HFxLim and Shim BioMedical Engineering OnLine 2010, 9:31
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therapy also provides both convective and diffusive transport simultaneously, but it uses
only dialysate solution, not replacement fluid. The pressure distribution along the length
of the dialyser in both the blood and dialysate compartment is an important factor in
convective transport. At the dialyser inlet of the blood circuit is a region of filtration, as
the blood pressure exceeds the dialysate pressure. Backfiltration occurs at the region of
the dialyser outlet of the blood circuit, as the dialysate pressure exceeds the blood pres-
sure.
Convective toxin clearance is a direct input parameter for the present simulation code
and is computed separately for each blood purification therapy by computing the UF
rate. The UF rate can be calculated as the product of the mean transmembrane pressure
(TMPm) and UF coefficient, shown in the following equations:
where Pb,in and Pb,out are the mean pressures at the dialyser inlet and outlet of the blood
circuit, respectively, Pd,in and Pd,out are those of the dialysate circuit, Kuf is the UF coeffi-
cient of the dialyser and Qf is the UF rate.
For the HF treatment, Pd,in and Pd,out were set to zero and Pb,in and Pb,out were obtained
from the in vitro reference data. Based on these pressures, TMPm was computed using
Eq. (1). We calculated the UF rate (Qf) in Eq. (2) from the UF coefficient obtained from
the in vitro experiment and the TMPm. Then, the convective toxin clearance for the HF
treatment was calculated with Eq. (A11) shown in the Appendix using the UF rate.
TMPm
Pbi n Pbo u t Pdi n Pdo u t =
+
−
+ ,, ,,
22
(1)
Q K TMPm fu f =⋅ (2)
Table 2: Parameter assignment of the mathematical model
Definition Value Units Ref.
KoAurea Diffusive mass transfer 
coefficient of the dialyser (urea)
967 mL/min Specs.
KoAB2M Diffusive mass transfer 
coefficient of the dialyser (B2M)
290 mL/min Specs.
Siurea Dialyser sieving coefficient 
(urea)
1S p e c s .
SiB2M Dialyser sieving coefficient 
(B2M)
0.8 Specs.
ηurea Transfer coefficient (urea) 0.77 L/min 6
ηB2M Transfer coefficient (B2M) 0.077 L/min 2
kf Water-transfer coefficient 0.24 L2/min/mmol 6
βurea Equilibrium ratio (urea) 1 6
βB2M Equilibrium ratio (B2M) 1 Est.
R Plasma water fraction 0.94 6
G Urea generation rate 6.24 mg/min 2
More detailed cellular and vascular parameters were described previously by Ursino et al. [6]. Est., 
estimated; Specs., from the FX60 dialyser specifications.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
http://www.biomedical-engineering-online.com/content/9/1/31
Page 5 of 16
In the HDF treatment, both diffusive and convective clearances exist simultaneously.
We set the dialysate flow rate to 300 mL/min as in the in vitro experiments. Diffusive
toxin clearance for the HDF treatment can be computed from Eq. (A8) in the Appendix
using the specified values of the blood and dialysate flow rate through the dialyser. Based
on the pressures and UF coefficients obtained from the in vitro experiments, UF rate was
calculated using Eq. (1) and (2). Then, convective toxin clearance for the HDF treatment
was calculated using Eqs. (A9) and (A10) shown in the Appendix.
HFx treatment also uses convection and diffusion simultaneously for toxin removal
but does not use replacement fluid, in contrast to other blood purification systems.
Therefore, to maintain a constant body fluid volume as in the other therapies, the net UF
should be zero by controlling the UF and backfiltration. In this HFx model, we set the
mean pressure at the dialyser inlet and outlet of the dialysate circuit equal to those in the
blood circuit to assign a zero net UF. The procedure to compute the UF rate is presented
in Eqs. (A12)-(A15) in the Appendix. Convective toxin clearance for the HFx treatment
is also calculated in Eq. (A11) in the Appendix using the UF rate.
In vivo test for model validation
In vivo experiments were performed to validate the present computational model. First,
we measured urea removal during blood purification in the dialysis unit of Kang's Clinic
in Seoul, Republic of Korea, during ten hemodialysis sessions using the AK95 roller
pump. Detailed conditions of the clinical measurements are presented in Table 3. Then,
we performed model simulations under conditions almost identical to the clinical set-
tings with respect to patient body weight, diffusive mass transfer coefficient of dialyser
for urea (KoAu), UF rate and blood and dialysate flow rates. The computed results of
urea removal were then compared with the in vivo clinical data.
Simulation models
The calculated convective toxin clearance was applied to the proposed mathematical
model. Three blood purification therapies (i.e., HF, HDF and HFx) were simulated for
both pulsatile and non-pulsatile systems according to the blood flow rate. Then, we com-
Figure 1 Schematic diagram of the mathematical model for a patient with the blood purification sys-
tem. There are two compartments for solute kinetics and three compartments for fluid dynamics inside body. 
(------), solute transfer; (----), fluid transfer; ic, intracellular; is, interstitial; pl, plasma;ex, extracellular; b, blood; d, di-
alysate; ηs, mass transfer coefficient of solute sbetween the intracellular and extracellular compartments; βs, 
equilibrium ratio of solute s; V, compartment volume; Ms, mass of the solute s; Qinf, flow rate of replacement flu-
id; Js, removal rate of solute s across the dialyser; Rv, fluid reabsorption rate at the venous capillaries; Fa, fluid fil-
tration rate at the arterial capillaries; kf, osmotic filtration coefficient at the cellular membrane; Q, extracorporeal 
flow rate; in, inlet; out, outlet. Modified from Ursino et al. [6] and Depner and Garred [2].Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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pared the total performances of urea and B2M for the pulsatile system with those for the
non-pulsatile system.
Next, we performed long-term simulations to compare the delivered treatment dose of
the pulsatile system with that of the non-pulsatile system. A treatment schedule of three
times per week, 4 h per treatment, was applied to each system. The EKRc and the stan-
dard (std) Kt/V indices were used to quantify the treatment dose. Here, the EKRc and std
Kt/V reflect the time-averaged concentration (TAC) and mean pre-treatment concentra-
tion (MPC), respectively [7-9]. According to the results of previous studies [9], the
required minimum values of EKRc and std Kt/V for an anuric patient with a total body
water volume of 40 L are 11 mL/min and 2, respectively. The indices are calculated using
the time-varying urea concentration profiles in the plasma compartment during 5 weeks
of simulation. The indices are defined in the Appendix.
Results
Parameter estimation and in vivo clinical test
The previous in vitro experimental result was used to determine the parameters of the
computational model, such as the inlet and outlet pressures of the blood circuits, and the
UF coefficient of the dialyser according to the blood pumping rate and pump type. Fig-
ure 2(a) shows the pressures at the dialyser inlet and outlet of the blood circuit according
to the blood flow rate and pump type. Under the same mean flow rate, the dialyser inlet
pressure of the pulsatile pump was higher than that of the non-pulsatile pump, whilst the
dialyser outlet pressure was almost identical for both pulsatile and non-pulsatile pumps.
Figure 2(b) shows the derived UF coefficient according to the blood flow rate and pump
type. The UF coefficient of the pulsatile pump was higher than that of the non-pulsatile
pump, and the difference in the UF coefficient between the two pumps decreased with
increasing blood flow rate.
As described in the Introduction, urea removal during blood purification was moni-
tored in vivo for short treatment times. We compared the measured data with computa-
tional results. As shown in Figure 3, the simulated plasma urea concentration profile was
very similar to the clinical results; both showed a concentration rebound phenomenon
after 4 h of treatment.
Toxin removal dynamics
Here, HF, HDF and HFx were simulated according to the pump type and blood flow rate.
Then, we assessed the effects of the pump type on the toxin clearance performances for
urea and B2M.
Table 3: Patient conditions and system settings for in vivodialysis experiments
Parameters Value Dimension
Number of patients 18
Patient body weight 73 ± 9 kg
Predialysis urea concentration 105 ± 12 mg/dL
KoAu*9 6 7 m L / m i n
Blood flow rate 300 mL/min
Dialysate flow rate 500 mL/min
UF rate 0.5 L/h
Treatment time 4 hLim and Shim BioMedical Engineering OnLine 2010, 9:31
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Figure 4(a) shows the percentage increase in computed urea clearance of the pulsatile
pump relative to that of the non-pulsatile pump according to the blood flow rate and
therapy. The increase in toxin clearance was highest in the HF treatment followed by the
HDF treatment over the entire range of flow rates computed (100-400 mL/min). In the
HF treatment, pulsatile pumping increased the urea clearance by a maximum of 122.7%
at a blood flow rate of 100 mL/min and a minimum of 10.5% at a blood flow rate of 400
mL/min. The percentage increase in urea clearance was reduced with increases in the
blood flow rate in HF. In HDF, urea clearance showed a maximum increase of 3.6% at a
blood flow rate of 300 mL/min and a minimal increase of 0.05% at a blood flow rate of
100 mL/min. In HFx, urea clearance showed maximum and minimum increases of 1.9%
and 0.03% at blood flow rates of 300 mL/min and 100 mL/min, respectively.
Figure 4(b) shows the percent increase in B2M clearance by pulsatile pumping for the
three types of therapy. The HF treatment showed the largest clearance increment fol-
lowed by the HDF treatment over the entire range of flow rates examined, similar to the
case of urea clearance. In HF, the percent increase of B2M clearance was identical to that
of urea clearance throughout the entire flow rate. In HDF, the B2M clearance increased
by a maximum of 8.3% at a flow rate of 300 mL/min and a minimum of 2.2% at a flow rate
of 100 mL/min. In HFx, the B2M clearance showed maximum and minimum increases
of 4.7% and 1.5% at flow rates of 300 mL/min and 100 mL/min, respectively. In the cases
of the HDF and HFx treatments, the increase in B2M clearance by pulsatile pumping was
larger than that of urea clearance.
Comparison of treatment doses
Figure 5 shows the computed EKRc and std Kt/V indices for 12-h weekly treatments in
the three types of therapy over the entire range of flow rates examined (100-400 mL/
min). For the HF treatment, EKRc and std Kt/V were on average 28% and 23% higher in
the pulsatile group than in the non-pulsatile group, respectively. However, the superior-
ity of the pulsatile pump was not remarkable in the HDF or HFx treatments, with incre-
ments of <2% in both treatments.
Figure 2 Variations in dialyser pressure and UF coefficients. Variation in (a) the pressure at the dialyser inlet 
and outlet (p < 0.02 for differences between P_in and NP_in) and (b) the UF coefficient of the dialyser (p < 0.02 
for differences between P and NP) for Qb = 100, 150, 250, and 300 according to pump type and the mean blood 
flow rate. P_in and P_out are the pressures at the dialyser inlet and outlet, respectively, in the pulsatile pump 
group. NP_in and NP_out are the pressures at the dialyser inlet and outlet in the non-pulsatile pump group. Kuf 
indicates the UF coefficient of the dialyser, P and NP are the UF coefficients in the pulsatile and non-pulsatile 
groups, respectively, and Qb indicates the mean blood flow rate.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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To satisfy the adequacy line of EKRc ≥ 11.0 and std Kt/V ≥ 2.0, the range of the ade-
quate blood flow rate was >200 mL/min for the HDF and HFx treatments under both
pulsatile and non-pulsatile conditions. However, for the HF treatment, the ranges of
blood flow rate to satisfy the adequacy line of EKRc ≥ 11.0 were >300 mL/min and 400
mL/min under pulsatile and non-pulsatile conditions, respectively. In addition, the
ranges of the blood flow rate for the HF treatment to guarantee the adequacy line of std
Figure 3 Comparison of the simulated results with the in vivo experiment. Percent changes of the intra-
cellular urea concentration (------) and plasma urea concentration (----) in the simulation and in vivo experiment 
().
Figure 4 Percent increase of dialyser clearance by pulsatile pumping. Difference in dialyser clearance be-
tween the pulsatile pump group and non-pulsatile pump group according to treatment type and mean blood 
flow rate. (a) Percent increase in urea clearance. (b) Percent increase in B2M clearance. Kurea and KB2M are the di-
alyser clearances for urea and B2M, respectively, and Qb indicates the mean blood flow rate.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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Kt/V ≥ 2.0 were 350 mL/min and 400 mL/min under pulsatile and non-pulsatile condi-
tions, respectively.
Discussion
In our previous in vitro study, we demonstrated the superiority of a pulsatile pump rela-
tive to a non-pulsatile or weak pulsatile pump in terms of the TMP and UF coefficients of
the dialyser [3]. Compared to the non-pulsatile pump, the pulsatile pump induced a
higher dialyser pressure, such as dialyser inlet pressure and TMP, and a higher UF coeffi-
cient at the same mean blood flow rate. The dialyser inlet pressure is influenced by the
flow impedance. Therefore, it is clear that the flow wave-form through the dialyser pro-
duced by the pulsatile pump induced higher flow impedance than did that produced by
the roller pump. As both blood pumps are flow generators and not pressure generators,
the pump inducing the higher impedance develops a higher fluid power to maintain the
target flow rate, and consequently produces a higher dialyser inlet pressure, which in
turn results in a higher TMPm and UF rate. In addition, an instantaneous high pressure
developed as the pulsatile pump increased the UF coefficient due to the reduction of
membrane layering. However, the difference in the UF coefficient between pulsatile and
roller pumps decreased as the pumping rate increased. This implies that an effective
pumping frequency exists for reducing membrane layering. In other words, a greater
pumping frequency makes the system less efficient in terms of the UF coefficient. These
results were limited to basic in vitro experiments to determine the UF efficiency of the
dialyser device itself.
In this study, theoretical evaluations of the apparatus and its application in patients
were performed to assess the effects of pulsatile flow on the efficiency of convective
toxin removal in blood purification systems. For this purpose, we devised a new mathe-
matical model, integrating the mass transfer model for the human body [6] with that for
the dialyser (Figure 1). For verification of the model, we simulated conventional hemodi-
alysis therapy for 4 h, and the computed urea concentration profile inside the body was
compared with clinical observations (Figure 3). Using the verified model, we theoreti-
cally predicted the effect of pulsatile pumping on convective toxin clearance (Figure 4)
Figure 5 Comparison of treatment doses; EKRc and std Kt/V. This shows the variations of (a) EKRc and (b) 
std Kt/V according to the mean blood flow rate under various treatment conditions and with various pump 
types. Qb indicates the mean blood flow rate, P_HF, P_HDF and P_HFx are pulsatile HF, HDF and HFx, respective-
ly, and NP_HF, NP_HDF and NP_HFx are non-pulsatile HF, HDF and HFx, respectively.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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and delivered treatment dose to patients with CRF (Figure 5) for various blood purifica-
tion therapies, i.e., HF, HDF and HFx.
HF treatment provides only convective toxin removal by UF and injection of replace-
ment fluid, whilst the HDF and HFx treatments provide diffusive toxin removal driven
by concentration differences between the blood and dialysate as well as convective toxin
removal. The convective toxin removal is dependent on the UF rate and sieving coeffi-
cient. The in vitro experiment demonstrated that pulsatile pumping improved the UF
rate by increasing the UF coefficient and the TMP (Figure 2). The improved UF rate
increased the convective toxin removal. Due to the effect of diffusive clearance, the con-
tributions of convective toxin removal to the total clearance in the HDF and HFx treat-
m e n t s  w e r e  l o w e r  t h a n  t h a t  i n  t h e  H F  t r e a t m e n t .  T h i s  e x p l a i n s  w h y  t h e  i n c r e a s e d
clearance by pulsatile pumping showed less benefit in the HDF and HFx treatments than
in the HF treatment as shown in Figure 4.
The sieving coefficient of the dialyser for B2M was 0.8, whereas the value for urea was
1. These observations indicated that in the HF treatment, B2M removal was 20% less
than that of urea under the same UF rate conditions. Thus, the convective clearance for
B2M was 20% less than that for urea in HF during which convective toxin clearance
occurred. However, HDF and HFx use the mechanisms of diffusive and convective toxin
removal simultaneously. In these cases, B2M removal was 20% less than that of urea by
the convective effect under the same UF rate conditions. In contrast, the diffusive mass
transfer coefficient of the dialyser for B2M [KoAB2M in Eq. (A8) in the Appendix] was
70% less than that for urea, which exceeded the 20% decrease compared to urea by the
convective effect. Therefore, in the case of HDF and HFx, the relative portion of convec-
tive toxin removal to diffusive toxin removal for B2M was more remarkable than that for
urea. These observations explain why the percentage increase in total clearance by pulsa-
tile pumping for B2M was more remarkable than that for urea, as shown in Figure 4.
To test the long-term performance of the three blood purification therapies and pre-
dict the effects of pump type on their performance, we simulated the therapies for 5
weeks and obtained the EKRc and std Kt/V indices for each case (Figure 5). In terms of
the EKRc and std Kt/V indices, HDF therapy showed the best performance, followed by
HFx therapy. HF therapy showed the poorest performance because it provided only con-
vective toxin removal, whilst the others provided convective and diffusive toxin removals
using the dialysis solution. However, the pulsatile effect on the delivered dose was best in
HF therapy, with neither HDF nor HFx showing a remarkable effect. As shown in Figure
5, the increases in delivered treatment doses of about 25% for both EKRc and std Kt/V in
HF therapy suggested that use of a pulsatile pump may become a practical alternative to
the conventional method with a non-pulsatile pump for HF treatment.
Although we developed a mathematical model of a CRF patient to assess several blood
purification methods, this model is not limited to chronic conditions. It can be used to
model an acute renal failure patient by modifying the mass transfer coefficients and con-
sidering residual renal function.
Several animal studies have shown that a blood purification system using a pulsatile
blood pump can effectively maintain a physiologically stable hemodynamic state, i.e., the
heart rate, arterial blood pressure, and hematocrit, and is a plausible alternative to sys-
tems using a conventional roller pump [10-12]. Furthermore, our in vitro experiment
showed that the hematocrit was maintained within the normal range during pulsatileLim and Shim BioMedical Engineering OnLine 2010, 9:31
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pumping. This means that no blood damage occurred due to the pulse peak pressure
during pulsatile blood purification therapy.
The use of a pulsatile blood pump in a blood purification system with a semipermeable
membrane was suggested to increase convective toxin removal, which could reduce both
treatment time and associated costs.
Although we provided simulated results for the test of the effects of pulsatile pump on
toxin removal, there are some limitations to our study. First, we have validated our
numerical patient model by comparing the simulated results with that the clinical test
only using a conventional non-pulsatile system. However, a comparison with the experi-
ment using pulsatile pump was not attempted because of no available pulsatile pump
that can be applied to patients among commercialized blood pumps. In addition, the
input parameters of the model, such as the pressures at the dialyser inlet and outlet and
UF coefficients, were estimated from in vitro rather than in vivo experiment.
Conclusions
We proposed a new mathematical model to assess the toxin removal efficiency of blood
purification systems in patients, integrating the mass transfer model for a human body
with a dialyser. In vivo experiments were also performed to verify clinically the model
results, respectively. Using the verified model, we simulated the effect of pulsatile pump-
ing on convective toxin clearance and delivered treatment dose to patients with CRF for
various blood purification therapies. Compared with non-pusatile pumping method, the
increases of urea and B2M clearances by pulsatile pump were highest in HF treatment
(122.7% and 122.7%, respectively), followed by HDF (3.6% and 8.3%, respectively) and
HFx (1.9% and 4.7%, respectively). EKRc and std Kt/V were on average 28% and 23%
higher, respectively, in the pulsatile group than in the non-pulsatile group in HF treat-
ment.
The superiority of pulsatile pumping is significant in HF treatment, which relies only
on convection for toxin removal. In both HDF and HFx treatments, the effectiveness of
pulsatile pumping on B2M removal, which depends more on convection compared to
urea removal, was more remarkable than that on urea removal. Finally, pulsatile system
will help any blood purification treatments, whose mechanism of toxin removal is
mainly convection, get better performance than conventional non-pulsatile system.
Appendix
A1. In vitro experiment for identification of model parameters
A schematic of the experiment is shown in Figure 6. The experiments were performed
for a pulsatile pump (T-PLS; BHK Inc., Seoul, Republic of Korea) and a non-pulsatile
pump (AK95 roller pump; Gambro Inc., Hechingen, Germany) under various flow rate
conditions from 100 to 400 mL/min in increments of 50 mL/min. Figure 7 shows the
pressure waveforms at the dialyser inlet generated by the two pumps. The AK95 pump
generated a very weak pulsatile flow that can be considered as almost non-pulsatile flow.
Each test was performed using bovine whole blood (heparin of 16 000 IU/L, Hct = 31%,
T = 37°C). In the dialysate circuit, we used the AK95 roller pump at a constant flow rate
of 300 mL/min for all test cases. A polysulphone dialyser (FX60; FMC Inc., Frankfurt,
Germany) was used with normal saline as the dialysis solution. An ultrasonic flow sensor
(T109; Transonic Systems Inc., Ithaca, NY) was placed in the blood circuit before the
dialyser to measure the flow rate. Four pressure sensors (Pressure transducer; SensysLim and Shim BioMedical Engineering OnLine 2010, 9:31
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Inc., Seoul, Republic of Korea) were inserted before and after the dialyser in the blood
and dialysate circuits. In the experiment, according to the pump type and flow rate, we
measured the four pressures (at the dialyser inlet and outlet of the blood circuit, and at
the dialyser inlet and outlet of the dialysate circuit) and UF coefficient of the dialyser.
Before starting the test, we recirculated bovine blood through the dialyser at 200 mL/
min for 2 h to develop a sufficient protein layer as suggested in a previous study [13].
The goal of the in vitro experiment was to establish reference data for the variation in
TMPm and UF coefficient according to pump type and flow rate. Thus, the parameters
such as TMPm and the UF coefficient for a specific condition of flow rate and pump type
can be obtained by interpolating the reference data.
A2. Governing equations of the mathematical model
The time derivatives of the intracellular fluid (Vic), interstitial fluid (Vis) and plasma (Vpl)
can be expressed as
dVic
dt
kOt Ot fi c i s −− [( ) ( ) ] (A1)
dVis
dt
kOt Ot
Ft Rt
fi c i s
av
=− () − () ()
+ () − ()
(A2)
dVpl
dt
Ft Rt Q av f =− + − 0( )( ) (A3)
Figure 6 Schematic diagram of the in vitro experiment with the dialysis circuit. There are two blood res-
ervoirs, one dialysate reservoir, one dialyzer, two blood pump, and four pressure sensor. P indicates the blood 
pump; P in the blood circuit can be the T-PLS pulsatile pump or the AK95 roller pump, and P in the dialysate 
circuit is the AK95 roller pump. S indicates a pressure sensor.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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where kf is the osmotic filtration coefficient at the cellular membrane, Oic and Ois are
the osmotic concentrations of the intracellular and interstitial compartments, respec-
tively, Fa is fluid filtration rate at the arterial capillaries, Rv is the fluid reabsorption rate at
the venous capillaries and Qf is the UF rate.
The time derivatives of the solute concentrations in the intracellular (Ms,ic) and extra-
cellular (Ms,ex) compartments are expressed as follows:
where ηs is the mass transfer coefficient of solute s at the cellular membrane, βs is the
equilibrium ratio of solute s, Cs,ic and Cs,ex are the intracellular and extracellular concen-
trations of solute s, respectively, Gs is the generation rate of solute s and Js is the solute
transfer rate through the dialyser membrane. We assumed Gurea to be 6.24 mg/min [2],
and Js is derived below:
dMsi c
dt
Ct Ct ss i c s s e x
,
,, =− () − () () hb (A4)
dMse x
dt
Ct Ct
GJ t
ss i c s s e x
ss
,
,, = () − () ()
+−()
hb
(A5)
Figure 7 Pressure wave forms at the dialyser inlet of the blood circuit. This is measured data from the in 
vitroexperiment using bovine whole blood as working fluid. Here, (-----) represents the pressure wave form pro-
duced by the T-PLS pulsatile pump and (-------) by the AK95 roller pump.Lim and Shim BioMedical Engineering OnLine 2010, 9:31
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where αs is the Gibbs-Donnan equilibrium ratio of solute s, r is the plasma water frac-
tion and Ks is the clearance of solute s. HDF or HFx treatments use simultaneous diffu-
sion and convection for toxin removal. Thus, toxin clearance is calculated as the sum of
diffusive clearance (Kds) and convective clearance (Kcs) as follows:
The diffusive clearance is expressed as
where KoAs is the diffusive mass transfer coefficient of the dialyser for solute s and Qb
and Qd are the blood and dialysate flow rates through the dialyser, respectively. The con-
vective clearance is expressed as
where Sis is the membrane sieving coefficient of solute s. T, termed the transmittance,
represents the mL/min increase in clearance for each mL/min of filtration and can be
calculated as follows:
The HF treatment uses only convection for toxin removal, and thus the convective
clearance is simply calculated as follows:
More detailed equations were described previously by Ursino et al. [6] and Depner and
Garred [2].
A3. Derivation of the internal UF rate for the HFx treatment
To calculate the internal UF rate in the HFx treatment model, we introduce the UF coef-
ficient per unit length, which is determined by dividing the UF coefficient by the dialyser
length as follows:
Jt Qt
r
Ct K
Qf t
Qb
s
r
Ct Ct
sf s p l s
sp l sd
() = () () −− () ⎛
⎝
⎜ ⎜
⎞
⎠
⎟ ⎟
() −
1
1 ,
,,
a ( ()
⎛
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where Kufl is the UF coefficient per unit length and L is the dialyser length. As a simpli-
fied approximation, the local pressure distributions along the dialyser fibres in the blood
and dialysate circuits are described as follows:
where x indicates the local position along the dialyser, Pb(x) and Pd(x) are the mean
pressures at local position x in the blood circuit and dialysate circuit, respectively. The
UF rate, which is the primary determinant of the convective clearance of the toxin, is cal-
culated as follows:
where M is a local point where neither UF nor backfiltration is generated. The internal
UF rate is directly related to the convective toxin clearance in the HFx treatment, and
therefore, the convective clearance for the HFx treatment is calculated using Eq. (A9) in
the Appendix.
A4. Definition of criterion indices
The time-averaged concentration of solute s (TACs) is calculated by integrating the con-
centration profile of the solute in the plasma compartments with respect to time as fol-
lows:
Equivalent renal clearance (EKRs) is calculated as follows:
EKRcs is the corrected value of EKRs for the normalised water volume, 40 L, as follows:
where V is the total body fluid.
The mean pre-treatment concentration of solute s (MPCs) is acquired by averaging the
pre-treatment concentrations in the plasma compartment at steady state, and the weekly
std Kt/V is then calculated as follows:
KK L ufl uf = / (A12)
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where t is the total time. All equations are adapted from Ursino et al. [6] and Depner
and Garred [2].
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